Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 20, 2024
IL-6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
A Reimer-Taschenbrecker, M Hess, M Davidovic, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 10, 2023
An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis
K Eyerich, J Krueger, M Stahle, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 19, 2016
Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwi-allergic donor
N Garzorz, J Thomas, B Eberlein, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 14, 2020
Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019
T Luger, T Dirschka, K Eyerich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 2, 2020
Transferability of suggested molecular classifiers for psoriasis and eczema to the Chinese population
M-N Xu, L Li, W Pan, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 30, 2015
Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases
N Garzorz, M Alsisi, A Todorova, et al.
The British Journal of Dermatology
|
November 10, 2019
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)
D Thaçi, A Pinter, M Sebastian, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 7, 2023
Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2
A Armstrong, K Eyerich, C Conrad, et al.
The British Journal of Dermatology
|
April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of response
M Augustin, D Thaci, K Eyerich, et al.
The British Journal of Dermatology
|
June 25, 2017
Sebum lipids influence macrophage polarization and activation
M Lovászi, M Mattii, K Eyerich, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 20, 2024
IL-6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
A Reimer-Taschenbrecker, M Hess, M Davidovic, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 10, 2023
An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis
K Eyerich, J Krueger, M Stahle, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 19, 2016
Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwi-allergic donor
N Garzorz, J Thomas, B Eberlein, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 14, 2020
Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019
T Luger, T Dirschka, K Eyerich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 2, 2020
Transferability of suggested molecular classifiers for psoriasis and eczema to the Chinese population
M-N Xu, L Li, W Pan, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 30, 2015
Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases
N Garzorz, M Alsisi, A Todorova, et al.
The British Journal of Dermatology
|
November 10, 2019
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)
D Thaçi, A Pinter, M Sebastian, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 7, 2023
Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2
A Armstrong, K Eyerich, C Conrad, et al.
The British Journal of Dermatology
|
April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of response
M Augustin, D Thaci, K Eyerich, et al.
The British Journal of Dermatology
|
June 25, 2017
Sebum lipids influence macrophage polarization and activation
M Lovászi, M Mattii, K Eyerich, et al.
Page
of 5